NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Bright Peak Therapeutics

Bright Peak Therapeutics

Private
BaselHealthcare & Life Scienceshttps://brightpeaktx.com/

Last Round

Series C

Jun 11, 2024

Total Funding Raised

$232M

Company Overview

Bright Peak Therapeutics is a biotechnology company that develops multifunctional precision immunotherapies for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

protein engineeringimmunotherapycytokine therapeuticsbiotechdrug discoveryprecision medicinechemically conjugatedoncologyautoimmune diseasetherapeutic indexclinical-stage biotechdrug pipelinebiopharmaprotein therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bright Peak Therapeutics Comparables

Compare Bright Peak Therapeutics with similar companies based on industry and business-model similarity.

Bright Peak Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synthekine
87%
Asher Biotherapeutics
84%
Anaveon
83%

Bright Peak Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 11, 2024
Series BJun 10, 2021
Series AJul 28, 2020

Key People

Founding team and executive leadership

Fred Wiklund

President CEO

Executive Team

Bright Peak Therapeutics Investors

Notable investors and investment history

Bright Peak Therapeutics investors
InvestorRounds
RA Capital ManagementSeries C, Series B
Northleaf Capital PartnersSeries C
KB InvestmentSeries C
KB InvestmentSeries C
Fidelity Management & Research CompanySeries B, Series C
Versant VenturesSeries B, Series C, Series A
Alexandria Venture InvestmentsSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2025

    John Schmid appointed to the Board of Directors.

  • Jan 6, 2025

    Will present at the 43rd Annual J.P. Morgan Healthcare Conference.

Bright Peak Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bright Peak Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bright Peak Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range37
Year Founded2017
Last FundingJun 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.